Kymera Therapeutics is set to announce data from a mid-stage clinical trial of its lead asset, KT-621, in eczema before the end of the year. This trial is being closely monitored by investors and healthcare professionals, as it is positioned to compete with Sanofi and Regeneron’s Dupixent, the top-selling drug in immunology. Dupixent has generated significant revenue and transformed treatment outcomes for millions of patients with conditions such as eczema and asthma.
Market analysts from Jefferies have labeled the upcoming results as “one of the most impactful I&I readouts this year.” The success or failure of KT-621 could have substantial implications for Kymera and its competitors, as well as for the millions of individuals living with eczema in the U.S. Additionally, positive results could enhance Kymera’s ambitions to address a wider range of immunological diseases, potentially leading to sales projections nearing $4 billion by 2035.
Source: statnews.com · Image: U.S. Department of Energy – Science – 278 030 003 (16582109522) by U.S. Department of Energy from United States, Public domain, via Wikimedia Commons
Start your 7-day trial and see what the database can do →
